Ifabric Stock Price, News & Analysis

iFabric Corp. (OTCQX: IFABF, TSX: IFA) is a manufacturing-focused company headquartered in Markham, Ontario. Through its wholly owned subsidiaries, including Intelligent Fabric Technologies (North America) Inc. (IFTNA) and Coconut Grove Pads Inc., the company develops, licenses, and commercializes performance apparel, advanced textile treatments and technologies, and specialty intimate apparel solutions.

iFabric operates through two strategic divisions. Its Intelligent Fabric Technologies division develops proprietary textile and surface-treatment technologies and applies them across performance apparel, medical protective apparel, consumer protective apparel, and adjacent product categories. These technologies are designed to add "intelligent" properties to fabrics, foams, plastics, and other surfaces, including antiviral and antibacterial characteristics, antimicrobial and anti-odor performance, water-repellence, UV protection, moisture management, and durable water repellency.

The company’s technology portfolio includes branded chemistries such as PROTX2®, an eco-friendly technology that provides antibacterial, antimicrobial, anti-mold, anti-mildew, and anti-odor protection, and ecoPEL™, a C0, PFC-free durable water repellent (DWR) finish aimed at combining water repellency with sustainability considerations. iFabric also references DryTX™ as a moisture-management technology used in textile applications. These technologies are used in medical and performance textiles and are intended to improve safety, comfort, and usability for end users.

The Coconut Grove division, operating as Coconut Grove Intimates, is described as a designer, manufacturer, distributor, licensor, and licensee of ladies’ intimate apparel products and accessories. Through this division, iFabric participates in the intimate apparel segment by offering products and related solutions under various licensing and distribution arrangements.

Business model and technology focus

According to multiple company disclosures, iFabric’s business model centers on developing proprietary textile technologies and then commercializing them through a mix of technology licensing, finished-goods programs, and partnerships with retailers and brands. IFTNA develops and supplies high-performance treatments that provide functional enhancements to textiles and other substrates. These enhancements include antimicrobial functionality, water repellence, moisture management, UV protection, and other performance attributes described by the company.

In addition to supplying chemistries, IFTNA also designs and produces finished products that showcase its technology platforms for major retailers and brand partners. Company communications highlight finished-product programs in categories such as performance apparel, medical scrubs, footwear, and bedding, where iFabric integrates its textile technologies into garments and other items sold under its own or partner brands.

Key technologies and applications

PROTX2® is a central technology in iFabric’s portfolio. The company describes PROTX2 as a powerful eco‑friendly technology that delivers antibacterial, antimicrobial, anti‑mold, anti‑mildew, and anti‑odor protection. When applied, each textile fiber is described as being transformed to provide protection against pathogens associated with healthcare‑associated infections and against persistent odors in medical and performance textiles. iFabric notes that PROTX2 is registered with the United States Environmental Protection Agency and is available for use throughout the United States.

ecoPEL™ is presented as a C zero, PFC‑free durable water repellent technology designed to meet apparel-industry demand for sustainability while maintaining performance. According to company materials, ecoPEL provides water repellency, is easy to apply, preserves fabric breathability, and is positioned as an eco‑friendly textile finish. iFabric also references DryTX™ as a moisture-management technology that offers wicking and quick-dry properties to enhance comfort and breathability in apparel.

These technologies are applied across multiple end uses. Company announcements describe deployments in high‑performance sports apparel, medical protective apparel, consumer protective apparel, scrubs, footwear, and bedding. iFabric also reports that its technologies have been adopted by brand and retail partners in various regions, including programs for Doctor’s Choice® scrubs, Roots® branded footwear, TUMI travel products, and Marks & Spencer’s Autograph collections, as well as the company-owned Verzus All Apparel brand and licensed bedding programs.

Subsidiaries and brand partnerships

Through Intelligent Fabric Technologies (North America) Inc., iFabric engineers and supplies its proprietary chemistries and integrates them into finished goods. IFTNA partners with global brands and retailers to deliver enhanced functionality across diverse end uses. Company communications describe collaborations where IFTNA designs, manufactures, and markets finished products that feature its textile technologies.

Examples disclosed by the company include:

• A license agreement with Mercury Athletics LLC, owner of the Doctor’s Choice brand, under which IFTNA designs, manufactures, and markets scrubs and medical apparel using PROTX2 and other technologies across healthcare categories and sales channels.
• A footwear program under the Roots® brand, where IFTNA designs, develops, and produces footwear for a Canadian wholesale club retailer, integrating proprietary performance technologies to enhance everyday use.
• A renewed license agreement with TUMI, Inc. to continue integrating PROTX2 antimicrobial solutions into linings and select body fabrics of TUMI travel products, including carry‑on luggage and accessories.
• An agreement for PROTX2 deployment in Marks & Spencer’s Autograph collections, with PROTX2 brand marks appearing on hang tags in stores and online for select products in the United Kingdom and European Union.
• The launch of Verzus All Apparel, a company-owned apparel brand featuring performance apparel designed with IFTNA textile technologies, initially offered through a Canadian wholesale club retailer.
• A license agreement with The Lad Collective Pty Ltd to manufacture, market, and distribute bedding products in North America that combine TLC’s patented functional utility innovations with IFTNA textile technologies such as PROTX2.

Through Coconut Grove Pads Inc., operating as Coconut Grove Intimates, iFabric participates in the intimate apparel market as a designer, manufacturer, distributor, licensor, and licensee of ladies’ intimate apparel products and accessories.

Clinical validation and infection-control focus

iFabric highlights clinical validation for its technologies. The company reports that a clinical trial titled “Antimicrobial-treated fabric scrubs can prevent pathogen proliferation on scrubs” was conducted by IFTNA at MemorialCare Saddleback Medical Center in Southern California and published in the Journal of Hospital Infection. According to iFabric, this trial demonstrated statistically significant reductions in bacterial loads on scrubs treated with PROTX2 and PROTX2 combined with ecoPEL compared to untreated scrubs in a real‑world healthcare setting.

The company states that previous attempts using other antimicrobial chemistries had not produced results of this magnitude and that the publication positions PROTX2 as a potential cornerstone solution in efforts to address healthcare‑associated infections. iFabric also outlines potential benefits associated with PROTX2 and ecoPEL in infection prevention, including reduced pathogen transfer on scrubs, possible reductions in hospital readmissions, and potential economic savings for healthcare facilities, as described in its communications.

Geographic footprint and listings

iFabric states that it is headquartered in Markham, Ontario, and is listed on the Toronto Stock Exchange (TSX: IFA) and trades on the OTCQX market under the symbol IFABF. Company materials describe a historical focus on North American brands and note that the deployment of PROTX2 into the United Kingdom and European Union represents an expansion beyond that focus, with Marks & Spencer adopting PROTX2 for select Autograph collection items.

Capital and financing framework

Company disclosures mention that iFabric has two strategic divisions operating through wholly owned subsidiaries and that it has arranged credit facilities to support growth. In one announcement, the company reports securing a trade finance facility with Ebury Partners Canada Ltd., described as unsecured and intended to provide additional financial flexibility and foreign-exchange risk management, supplementing an existing secured credit facility with a Canadian chartered bank. iFabric states that management believes these facilities provide working capital support for its sales growth objectives.

Position within the textile and apparel ecosystem

Across its communications, iFabric presents itself as active in performance apparel, advanced textiles, fabric treatments, and intimate apparel. Rather than focusing solely on commodity textiles, the company emphasizes functional enhancements such as antimicrobial performance, water repellency, and moisture management. Its collaborations with brands and retailers in categories like travel goods, medical apparel, lifestyle apparel, footwear, and bedding illustrate how its technologies are integrated into products that reach consumers through partner channels.

FAQs about iFabric Corp. (IFABF)

• What does iFabric Corp. do?
  According to the company, iFabric develops and commercializes performance apparel, advanced textile treatments and technologies, and specialty intimate apparel solutions through subsidiaries Intelligent Fabric Technologies (North America) Inc. and Coconut Grove Pads Inc.
• Where is iFabric headquartered?
  Company disclosures state that iFabric is headquartered in Markham, Ontario.
• On which exchanges does iFabric stock trade?
  iFabric reports that it is listed on the Toronto Stock Exchange under the symbol IFA and trades on the OTCQX market under the symbol IFABF.
• What are iFabric’s main business divisions?
  The company describes two strategic divisions operated through wholly owned subsidiaries: Intelligent Fabric Technologies (North America) Inc., focused on performance and protective textile technologies and finished products, and Coconut Grove Pads Inc., operating as Coconut Grove Intimates in ladies’ intimate apparel.
• What is PROTX2®?
  PROTX2 is described by iFabric as an eco‑friendly technology that provides antibacterial, antimicrobial, anti‑mold, anti‑mildew, and anti‑odor protection for medical and performance textiles, with registration noted with the United States Environmental Protection Agency.
• What is ecoPEL™?
  ecoPEL is presented as a C zero, PFC‑free durable water repellent technology that provides water repellency while preserving fabric breathability and addressing sustainability considerations in textile finishing.
• In which product categories are iFabric’s technologies used?
  Company communications reference use of its technologies in high‑performance sports apparel, medical protective apparel, consumer protective apparel, scrubs, footwear, bedding, travel products, and intimate apparel.
• Who are some of iFabric’s disclosed brand and retail partners?
  Public announcements mention collaborations involving Doctor’s Choice, Roots, TUMI, Marks & Spencer’s Autograph collections, and a Canadian wholesale club retailer carrying Verzus All Apparel and Roots footwear, as well as a license agreement with The Lad Collective for bedding.
• Has iFabric reported clinical evidence for its technologies?
  Yes. The company reports that a clinical trial on antimicrobial-treated scrubs using PROTX2 and ecoPEL was published in the Journal of Hospital Infection and demonstrated statistically significant reductions in bacterial loads on treated scrubs compared to untreated scrubs in a hospital setting.
• How does iFabric describe its approach to international expansion?
  In its communications, iFabric notes that expanding PROTX2 deployment into the United Kingdom and European Union through Marks & Spencer represents a move beyond its longstanding North American focus and supports broader regional market exposure for its technologies.